OncoMatch/Clinical Trials/NCT06654297
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
Is NCT06654297 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Camrelizumab and Palbociclib(100mg) for esophageal squamous cell carcinoma.
Treatment: Camrelizumab · Palbociclib(100mg) · Palbociclib(125mg) — The purpose of this study is to explore the safety and feasibility of anti-programmed cell death 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Palbociclib, as a new neoadjuvant treatment regimen for patients with resectable esophageal squamous cell carcinoma (ESCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1B-T3N1-3M0, CT3N0M0 (AJCC/International Union Against Cancer (UICC) 8th Edition)
The primary tumor should be located in the thorax and evaluated resectable( cT1b-T3N1-3M0, cT3N0M0) by CT/MRI/EUS. The stage of tumor is T4b (AJCC/International Union Against Cancer (UICC) 8th Edition) and cannot be resected.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Currently undergoing other chemotherapy
Cannot have received: radiotherapy
Currently undergoing other...radiotherapy
Cannot have received: targeted therapy
Currently undergoing other...targeted therapy
Cannot have received: immunotherapy
Currently undergoing other...immunotherapy
Cannot have received: investigational drug
Received any investigational drug within 4 weeks prior to the first dose
Lab requirements
Blood counts
blood routine tests should be basically normal
Kidney function
kidney function should be basically normal
Liver function
liver function should be basically normal
Cardiac function
heart function should be basically normal; grade II and above cardiac dysfunction (NYHA criteria), ischemic heart diseases, etc. are excluded
Blood routine tests, as well as lung, liver, kidney, and heart functions should be basically normal. Presence of serious medical diseases, such as grade II and above cardiac dysfunction (NYHA criteria), ischemic heart diseases, etc.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify